NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
69660-0201-91 | 69660-0201 | Rucaparib | Rubraca | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 19, 2016 | Dec. 31, 2025 | In Use |
69660-0202-91 | 69660-0202 | Rucaparib | Rubraca | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | May 1, 2017 | July 31, 2025 | In Use |
69660-0203-91 | 69660-0203 | Rucaparib | Rubraca | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 19, 2016 | July 31, 2025 | In Use |
59572-0983-01 | 59572-0983 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Jan. 4, 2010 | In Use | |||
00703-3071-01 | 00703-3071 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | April 14, 2020 | In Use | |
00703-4004-01 | 00703-4004 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | April 14, 2020 | In Use | |
63323-0926-88 | 63323-0926 | Romidepsin | Romidepsin | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Oct. 12, 2021 | In Use | ||
00703-3125-08 | 00703-3125 | Romidepsin | Romidepsin | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Aug. 1, 2018 | Oct. 31, 2021 | No Longer Used | |
59572-0984-01 | 59572-0984 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jan. 4, 2010 | In Use | ||
46026-0983-01 | 46026-0983 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Nov. 5, 2009 | May 28, 2010 | No Longer Used | |
69656-0101-02 | 69656-0101 | Rolapitant | Varubi | 90.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 7, 2015 | Oct. 31, 2021 | No Longer Used |
00069-0238-01 | 00069-0238 | Rituximab-pvvr | Ruxience | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan. 23, 2020 | In Use | |
00069-0249-01 | 00069-0249 | Rituximab-pvvr | Ruxience | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan. 23, 2020 | In Use | |
63459-0103-10 | 63459-0103 | Rituximab-abbs | Truxima | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | May 4, 2020 | In Use | |
63459-0104-50 | 63459-0104 | Rituximab-abbs | Truxima | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | May 4, 2020 | In Use | |
50242-0108-01 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | June 22, 2017 | In Use | |
50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | June 23, 2017 | In Use | |
50242-0109-01 | 50242-0109 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | June 22, 2017 | In Use | |
50242-0053-06 | 50242-0053 | Rituximab | Rituxan | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov. 26, 1997 | In Use | |
50242-0051-10 | 50242-0051 | Rituximab | Rituxan | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | June 3, 2019 | In Use | |
50242-0051-21 | 50242-0051 | Rituximab | Rituxan | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov. 26, 1997 | In Use | |
73207-0101-30 | 73207-0101 | Ripretinib | QINLOCK | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Oral | May 15, 2020 | In Use | |
73207-0101-31 | 73207-0101 | Ripretinib | QINLOCK | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Oral | May 15, 2020 | In Use | |
00078-0909-61 | 00078-0909 | Ribociclib and letrozole | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
00078-0860-01 | 00078-0860 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0867-14 | 00078-0867 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0867-42 | 00078-0867 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0874-21 | 00078-0874 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0874-63 | 00078-0874 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | March 22, 2023 | In Use | |
00003-4040-12 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec. 5, 2023 | In Use | |
00003-4040-60 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec. 5, 2023 | In Use | |
72974-0120-01 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Dec. 18, 2020 | In Use | |
72974-0120-97 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Oct. 21, 2021 | In Use | |
72974-0120-95 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Jan. 27, 2023 | In Use | |
50419-0171-00 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sept. 27, 2012 | In Use | |
50419-0171-01 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sept. 27, 2012 | In Use | |
50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sept. 27, 2012 | In Use | |
50419-0171-04 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sept. 27, 2012 | In Use | |
50419-0171-06 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | May 1, 2021 | In Use | |
00024-5150-10 | 00024-5150 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | July 12, 2002 | In Use | |||
00024-5151-75 | 00024-5151 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | June 1, 2006 | In Use | |||
00002-7669-01 | 00002-7669 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | April 21, 2014 | In Use | |
00002-7678-01 | 00002-7678 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | April 21, 2014 | In Use | |
43598-0505-01 | 43598-0505 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
43598-0505-10 | 43598-0505 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
43598-0505-30 | 43598-0505 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
71209-0082-01 | 71209-0082 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
71209-0082-05 | 71209-0082 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
71209-0082-11 | 71209-0082 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 13, 2021 | In Use | ||
71209-0082-13 | 71209-0082 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
72241-0010-05 | 72241-0010 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
72241-0010-11 | 72241-0010 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
72241-0010-13 | 72241-0010 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
72241-0010-22 | 72241-0010 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 30, 2017 | In Use | ||
66993-0417-02 | 66993-0417 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 1, 2014 | April 30, 2018 | No Longer Used | |
66993-0417-30 | 66993-0417 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 1, 2014 | June 30, 2018 | No Longer Used | |
66993-0417-88 | 66993-0417 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 1, 2014 | June 30, 2018 | No Longer Used | |
50090-6177-01 | 50090-6177 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 18, 2022 | In Use | ||
50228-0306-20 | 50228-0306 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
50228-0306-30 | 50228-0306 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
54868-4170-00 | 54868-4170 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | May 11, 2000 | In Use | ||
54868-4170-01 | 54868-4170 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | May 11, 2000 | In Use | ||
65162-0057-03 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
65162-0057-09 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
65162-0057-10 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
65162-0057-11 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
65162-0057-33 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
65162-0057-50 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 20, 2016 | In Use | ||
00002-4165-02 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Dec. 31, 2017 | No Longer Used | |
00002-4165-07 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Nov. 30, 2017 | No Longer Used | |
00002-4165-30 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 31, 2018 | No Longer Used | |
00002-4165-34 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 25, 2011 | No Longer Used | |
00002-4165-61 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 10, 2010 | April 3, 2015 | No Longer Used | |
00002-4165-79 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 25, 2011 | No Longer Used | |
00002-4165-99 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 6, 2009 | March 5, 2012 | No Longer Used | |
65862-0709-01 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
65862-0709-03 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
65862-0709-10 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
65862-0709-22 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
65862-0709-30 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
65862-0709-99 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | In Use | ||
00093-7290-01 | 00093-7290 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 28, 2014 | In Use | ||
00093-7290-10 | 00093-7290 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 28, 2014 | April 30, 2018 | In Use | |
00093-7290-56 | 00093-7290 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 28, 2014 | In Use | ||
43353-0253-60 | 43353-0253 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 15, 2016 | In Use | ||
00179-0151-70 | 00179-0151 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | May 29, 2014 | Jan. 31, 2017 | In Use | |
00179-0212-70 | 00179-0212 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | July 8, 2016 | Dec. 31, 2016 | In Use | |
00179-0220-70 | 00179-0220 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | March 31, 2018 | In Use | |
00591-2367-01 | 00591-2367 | Raloxifene Hydrochloride | Raloxifene | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 18, 2015 | In Use | ||
00591-2367-10 | 00591-2367 | Raloxifene Hydrochloride | Raloxifene | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 18, 2015 | In Use | ||
00591-2367-30 | 00591-2367 | Raloxifene Hydrochloride | Raloxifene | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 18, 2015 | In Use | ||
49999-0458-30 | 49999-0458 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 7, 2012 | Dec. 31, 2014 | No Longer Used | |
52343-0137-01 | 52343-0137 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2015 | May 1, 2020 | No Longer Used | |
55289-0266-30 | 55289-0266 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb. 23, 2011 | July 17, 2018 | No Longer Used | |
69189-0418-01 | 69189-0418 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | March 1, 2015 | May 24, 2017 | No Longer Used | |
69189-0678-01 | 69189-0678 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | July 21, 2016 | May 24, 2017 | No Longer Used | |
69189-2367-01 | 69189-2367 | Raloxifene Hydrochloride | Raloxifene | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | May 9, 2016 | May 24, 2017 | No Longer Used | |
42291-0726-10 | 42291-0726 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 3, 2014 | In Use | ||
42291-0726-90 | 42291-0726 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 3, 2014 | Sept. 19, 2018 | In Use |
Found 10,000 results in 5 milliseconds — Export these results